NEW YORK – AnPac Bio-Medical Science and Roche Pharmaceuticals China on Thursday said that they have teamed up to combine their respective cancer screening, diagnostic, and treatment-guiding technologies into personalized product lines.
Specifically, Philadelphia-based AnPac, which has two clinical laboratories in China, and Roche China will create packages of their products and services, which they say will help improve test affordability in addition to personalized care.
For its part of the product package, AnPac Bio will provide its Cancer Differentiation Analysis detection technology, which uses a proprietary algorithm to synthesize and analyze biophysical signals at the cellular, protein, and molecular levels in patients' blood samples, in turn generating a personalized cancer risk assessment for each patient. Roche, meanwhile, will bring its subsidiary Foundation Medicine's FoundationOne CDx comprehensive genomic profiling test, which uses tumor next-generation sequencing to guide targeted treatment and immunotherapy recommendations.
The combined services will comprise a "full solution," according to the partners, through which the general population in China will have access to cancer risk testing, and should they receive a full diagnosis, will also have access to the NGS test for therapy selection.